solid tumorsNational Cancer InstituteOKT3NCIIL-21U.S. Department of Health and Human ServicesNeoExpandREP
…(TCR-T cells) has shown promising clinical efficacy in treating solid tumors. Clinical responses in solid tumors may require transfer of ten…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 286 of 2459oxaliplatinmetastatic melanomaNational Cancer Instituteirinotecanmelanomaepithelial cancermetastatic cancermetastatic colorectal cancerClavien-Dindo
…c therapy, and 44% of patients with epithelial cancer had prior oxaliplatin or irinotecan exposure. Minimally invasive resection was perfor…
non-small cell lung cancerDenosumabCapmatinibNSCLCAtezolizumabCarboplatinAtezolezumabPemetrexedPemetexedCampatinib
…this patient.Methods A 65 year-old Ex smoker male with advanced non-small cell lung cancer was found to have both high-level MET amplification and high PD…
nivolumabipilimumabNSCLC
…comes, and overall survival (OS) in NSCLC patients treated with nivolumab.Methods This observational, multicenter, prospective study enro…
melanomametastatic melanomamelanoma brain metastasesipilimumabnivolumabMBM
…and concurrent stereotactic radiosurgery in immunotherapy-naïve melanoma brain metastases. Cancers (Basel). 2024 Nov 5;16(22):3733. doi:…
ipilimumabenzalutamidemetastatic castration-resistant prostate cancermCRPCpancreatic ductal carcinomaJ Clin Oncolprostate cancerAtezolizumab
…, Gravis G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patient…
paclitaxeltrastuzumabramucirumabevorpaceptevoevo-TRPevo-basedTRPHER2-overexpressing gastric/gastroesophageal cancer (GC)
…d PFS in combination with trastuzumab (T), ramucirumab (R), and paclitaxel (P) in advanced, previously treated HER2+ gastric/gastroesophag…
hepatocellular carcinomaHCCliver cancercancerC3aR-AT
…Background Despite recent advances, hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, part…
99.0%
melanomaNSCLChead and neck squamous cell carcinomatriple-negative breast cancernon-small cell lung cancerYale UniversityHNSCCYale Human Investigation CommitteeTNBCICIs
…c data from seven cohorts spanning four cancer types (n = 314): melanoma; n=100, NSCLC; n=117, TNBC; n=42, and HNSCC; n=55. Each cancer …
Q-1802OxaliplatinPeking University Cancer HospitalXELOXcapecitabineadvanced GC/GEJ
…. Patients with untreated advanced GC/GEJ are administered with Q-1802 (IV, Q2W) respectively at 10 mg/kg and 20 mg/kg dose level in c…
tislelizumabsintilimabInnoPCVnon-small cell lung cancerAffiliated Hospital of Guizhou Medical UniversityECOG Performance StatusINV002Anti-PD-1 monoclonal antibody
… Group performance status of 0 or 1. Eligible patients received tislelizumab (200 mg, IV Q3W) or sintilimab (200 mg, IV Q3W) for a lead-in p…